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Human immunodeficiency virus (HIV)-associated anaplastic large cell lymphoma (ALCL) is not so common, and
anaplastic lymphoma kinase protein (ALK)-negative ALCL is rare and has a low survival rate. We report a case of a
31-year-old Japanese man diagnosed with HIV-associated ALK-negative ALCL who presented with long-lasting fever
of unknown origin. The diagnosis was based on a full work-up that included inguinal lymph-node biopsy. Eight-
cycle chemotherapy that included cyclophosphamide, doxorubicin, vincristine, and prednisone in addition to
antiretroviral therapy for HIV infection provided a complete remission of his ALCL and over 5-year survival for him.
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It is well documented that human immunodeficiency
virus (HIV)-infected patients have high rates for the de-
velopment of various malignant diseases in comparison
with healthy people (Sigel K et al., 2011). Acquired im-
munodeficiency syndrome (AIDS) patients often develop
Kaposi’s sarcoma and non-Hodgkin lymphomas (NHLs).
However, there are an increasing number of cases compli-
cated with malignant diseases, such as other malignant
lymphomas (ML), leukemia, and other various carcinomas
even in non-AIDS patients (Lewden C et al., 2008; Philips
AA et al., 2009; Simard EP et al., 2010).
Few reports of T-cell lymphoma in HIV-infected pa-
tients have been presented (Arzoo KK et al., 2004; Castillo
JJ et al., 2011). Anaplastic large cell lymphoma (ALCL) is a
distinct subtype of peripheral T-cell lymphoma (PTCL)
characterized by the expression of CD30 in lymphoma
cells. Like aggressive B-cell NHLs, the risk of developing
PTCL is also increased in the setting of HIV infection.
HIV-associated ALCL cells rarely expressed anaplastic
lymphoma kinase protein (ALK) (Perez K et al., 2010).
The 5-year overall survival of ALK- positive and -negative
patients is 79% and 46%, respectively (Gascoyne RD et al.* Correspondence: furusyo@gim.med.kyushu-u.ac.jp
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HIV infection who was diagnosed with ALK-negative
ALCL with complete remission and long-time survival by
antiretroviral therapy (ART) for HIV and chemotherapy.Case presentation
A 31-year-old Japanese man who had sex with men
complained of lasting fever over 38°C, severe general
fatigue, and an 8.5% reduction of body weight over the
preceding four months, for which he had visited a
nearby hospital in March 2008. A HIV screening test
was positive and he was transferred to Kyushu University
Hospital after 10 days at the original hospital. On ad-
mission, physical examination revealed a fever of 39.8°C,
blood pressure 110/69 mmHg, pulse rate 110 beats
per min, body weight 54 kg, height 168 cm, and body
mass index 19.1 kg/m2. Examination of the oral cav-
ity showed small mucosal nodules, suggesting oral
Candidiasis and mild hepatosplenomegaly without
any other lymphadenopathy.
Table 1 shows the patient’s biochemical laboratory data
on admission. The CD4 cell count and HIV viral load were
26/μL and 100,000 copies/mL, respectively. Epstein-barr
virus and Cytomegalovirus infection were ruled out in
his sera. Plasma β-D glucan and other antigens for fun-
gal infections, such as Cryptococcus neoformans andOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Laboratory data on admission
Red cell count (/mm3) 358 × 104 Rapid plasma reagin Negative
Hemoglobin (g/L) 93 TPHA (titer) 320
White-cell count (/mm3) 2680 Chlamydophila trachomatis IgG/IgA Positive / Negative
Platelet count (/mm3) 4.9 × 104 Soluble interleukin II receptor (U/mL) 2056
Erythrocyte sedimentation rate (mm/hr) 81 Cryptococcus Antigen (U/mL) <3
Serum Creatinine (mg/L) 6.7 Toxoplasma Antibody IgG (U/mL) <100
Serum glucose (mg/dL) 101 Aspergillum Antibody IgG (U/mL) <0.1
Serum total bilirubin (mg/L) 4.0 Quanti FERON-E (U/mL) 0.12
Serum total protein (g/L) 74 Quanti FERON-C (U/mL) 0.1
Serum albumin (g/L) 31 β-D glucan (pg/mL) 4.01
Alkaline phosphatase (U/L) 246 EBV Early antigen IgG Negative
Aspartate aminotransferase (U/L) 51 EBV Capsid antigen Negative
Alanine aminotransferase (U/L) 43 EBV Nuclear antigen -IgG Negative
Lactate dehydrogenase (U/L) 432 CMV Antibody IgG 80
Serum amylase (U/L) 127 CMV Antibody IgM <0.1
Serum creatine kinase (U/L) 99 CMV antigenemia (C7HRP) Negative
Serum CRP (mg/dL) 2.94 HIV RNA (copies/mL) 100,000
HBs antigen Negative CD4 (/μL) 26
HCV Antibody Negative CD8 (/μL) 132
HTLV-1 Antibody Negative CD4/CD8 ratio 0.2
HBs hepatitis B surface, HCV Hepatitis C virus, HTLV Human T cell leukemia virus, TPHA Treponema pallidum hemaggulutination assay, EBV Epstein-Barr virus,
CMV Cytomegalovirus.
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several times from blood, urine, and sputum were all
negative.
Imaging tests such as chest and abdominal X-ray;
cervical, thoracic and abdominal computed tomography
(CT) scans; head, trunk, and total spinal magnetic res-
onance imaging (MRI); and gallium scintigraphy were
done. Thoracic CT showed some small masses (<5 mm)
in the bilateral lower lobes of the lung. The first MRI
and gallium scintigraphy showed high signals in the
spine and sacroiliac joint, but indicated no other spe-
cific findings. Bone marrow aspiration showed normo
to hypercellular marrow tissue. A lower gastrointestinal
endoscopy showed no other abnormalities, such as ma-
lignant diseases.
Although there was no evidence of Mycobacterium
avium complex (MAC) infection, we suspected MAC in-
fection and at day 2 after admission and began an oral,
multi-drug regimen that included rifampicin 600 mg/day,
clarithromycin 800 mg/day, and ethambutol 750 mg/day.
Because these treatments were not effective, we considered
the possibility of HIV-associated fever, and started ART
with raltegravir, tenofovir/emtricitabine, and lopinavir/
ritonavir at hospital day 13 after admission. After induc-
tion of ART therapy, body temperature once decreased to
under 37°C, but again increased to over 39°C after a few
days. At 12 days after induction of ART, his CD4 cellcount increased from 26/μL to 72/μL and HIV viral load
decreased from 100,000 copies/mL to 59 copies/mL. Con-
sidering the possibility of drug induced fever, we stopped
all drugs for the MAC and Candida infections, but fever
over 39°C continued.
A second thoracic CT showed another lesion in the
left lung, and on that occasion his blood was positive by
Quanti FERON-TB Gold In Tube assay, which is used
for the screening of latent tuberculosis. To rule out pul-
monary tuberculosis, bronchoscopy was done, but the
bronchoalveolar lavage indicated no pulmonary diseases.
Repeated cultures of sputum, gastric fluid, and bone mar-
row tissue were negative for Mycobacterium tuberculosis
and MAC. The second trunk MRI at hospital day 31
showed high signals in the spine and sacroiliac joint. At
hospital day 38, the second gallium scintigraphy showed
high up-take of systematic bone marrow and in the right
sacroiliac joint (Figure 1A and 1B).
At hospital day 56, fluoro-2-deoxy-D-glucose positron
emission tomography revealed abnormal uptake in some
ribs, the spine, sacroiliac joint, mediastinal lymph nodes,
and bilateral hilum of the lung (Figure 1C and 1D). We
strongly suspected malignant lymphoma, although there
was little up-take in the inguinal lymph node. Because
of newly palpable swelling in the right inguinal lymph
node, biopsy was done. The tissue section showed a
variable proportion of large hallmark cells with eccentric
A B C D
Figure 1 Gallium scintigraphy at hospital day 38 and fluoro-2-deoxy-D-glucose positron emission tomography at hospital day 56.
Images of gallium scintigraphy show high up-take (arrows) in the systemic bone marrow (1A) and right sacroiliac joint (1B). Images of fluoro-2-
deoxy-D-glucose positron emission tomography (1C and 1D) show abnormal uptake in some ribs, the spine, sacroiliac joint, mediastinal lymph
nodes, and bilateral hilum of lung.
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region near the nucleus and many scattered, atypical
large lymphoid cells together with small lymphocytes
(Figure 2A). Atypical lymphoid cells showed large,
atypical lymphoid cells with bizarre nuclei (Figure 2B).
Immunohistochemically, these cells were positive for
T-cell markers (CD3, CD45RO), CD30 and CD4, but
negative for B-cell markers (CD20, CD79a) and ana-
plastic lymphoma kinase (ALK) (Figure 2C and 2D).
Other types of T-cell lymphoma, such as ATL, were
ruled out. These features confirmed T-cell lymphoma
of the ALK-negative ALCL type. At the same time, flow
cytometry indicated the likely pattern of ALCL. The
second bone marrow aspiration showed normal to
hypercellular marrow tissue. The final diagnosis was
HIV-associated ALK-negative ALCL (stage IV) in May
2008. His performance status was 0 and age adjus-
ted International Prognostic Index was 3. Immediately,
chemotherapy (cyclophosphamide, doxorubicin, vin-
cristine and prednisone; CHOP) was administered in
eight courses done at an interval of three weeks. There
was a little reduction of the white blood cell count due
to chemotherapy and no other toxicity related to the
therapy was shown, thus no dose reduction was neces-
sary at any time during the therapy. After induction of
an eight-cycle course of CHOP, systemic lymph node
swelling was markedly decreased and clinical symp-
toms and laboratory data showed complete remission.After completion of CHOP therapy, ART was contin-
ued and led to a favorable increase of CD4 cells. The
patient has had no recurrence of ALCL until August
2013, suggesting the overall survival period of the
patients after diagnose is 63 months.
Discussion
The definition of ALCL has evolved since its original
description in 1985 (Stein H et al., 1985), and ALCL
represents a well-characterized group of T-cell lymph-
omas. Currently, the World Health Organization classifica-
tion for ALCL represents a unique diagnostic subcategory,
which comprises approximately 3% of adult and 10%-30%
of childhood NHLs (Azoo KK et al., 2004). The defining
features of ALCL include proliferation of predominantly
large lymphoid cells with a characteristic growth pattern
and strong expression of CD30. There are three groups
of ALCL according to molecular and clinical criteria:
Primary systemic ALK-positive anaplastic lymphoma,
ALK-negative primary systemic anaplastic lymphoma,
and primary cutaneous anaplastic lymphoma. ALK ex-
pression is caused by chromosomal translocation, most
commonly t (2; 5) (Philips AA et al., 2009; Simard EP
et al., 2010). Most ALCLs in children and younger
adults express ALK protein and show favorable prognosis,
while ALK-negative ALCLs are more heterogeneous and
have a poor prognosis (Stein H et al., 2000). ALK-negative
ALCL is highly associated with older men and shows poor
Figure 2 Pathology of the right inguinal lymph node. Panels 2A and 2B show hematoxylin eosin stain of the inguinal lymph node. Panel 2C
shows the stain for CD 30 and Panel 2D for anaplastic lymphoma kinase (ALK).
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the literature, HIV-associated ALCL cells rarely expressed
anaplastic lymphoma kinase (Perez K et al., 2010). More-
over, the treatment response, prognosis, and long-term
survival of ALK-negative ALCL are far worse than for
ALK-positive ALCL (Stein H et al., 2000). For our patient,
ART and CHOP were highly effective and resulted in
complete remission. Some cases of HIV-associated ALCL
treatment with etoposide, vincristine, doxorubicin, cyclo-
phosphamide, and prednisone chemotherapy have been
reported (Nagajothi N et al., 2007). It is unclear which
chemotherapy for HIV-associated ALK-negative ALCL is
the most effective due to the small number of cases. More
data is needed to improve the treatment options for these
patients.
There are several reports that ART has a supportive ef-
fect on chemotherapy for HIV-associated ML. Many prior
studies have focused on changes in risk for more common
non-AIDS-defining malignancies in HIV-infected patients
undergoing ART, and more recent studies have evaluated
malignancy risk with respect to individual ART use,
including the effect of specific antiretroviral agents, ART
drug classes, and the duration of ART. Other studies have
evaluated the association of immune function and the risk
associated with non-AIDS-defining malignancies, which
may mediate the observed relationships of cancer risk and
ART use (Silverberg MJ et al., 2009). The number of
patients with HIV-associated T-cell lymphoma remains
small. Therefore, better and more effective treatmentoptions for patients with HIV-associated ALK-negative
ALCL will be a welcome addition to the presently used
regimens.
To date, the occurrence of ALCL in HIV-positive indi-
viduals is limited to a few case reports and small case
series (Perez K et al., 2010; Genet P. 2012). A total of 37
cases of HIV-associated ALCL were identified after
reviewing the available published literature (Perez K
et al., 2010). Analysis of these cases showed that this
group of HIV-infected patients was on average 38 years
of age with a male-to-female ratio of 4:1, and a reported
median CD4 cell count of 83 cells/mm3. Epstein-Barr
virus infection was associated with one-third of the
cases. These lymphomas manifested almost exclusively
with extranodal involvement and exhibited a very ag-
gressive clinical course. The median overall survival was
only 5 months. The administration of chemotherapy
and early stages at presentation were identified as good
prognostic factors, while the use of ART showed a statis-
tical trend toward improved survival in HIV-associated
ALCL. Our case has suffered from stage IV ALCL with an
extremely low baseline CD4 count (26/μL) not Epstein-
Barr virus infection, but has survived more 5 years with-
out remission by chemotherapy and ART.
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